Q2 2020 Anika Therapeutics Inc Earnings Call
Thank you for standing by.
The conference operator, welcome to the Q2 2020, Anca Therapeutics earnings Conference call.
As a reminder, all participants are in listen only mode and the conference is being recorded.
After the presentation, there will be an opportunity to ask questions. He joined a question can you give me press Star then one on your telephone keypad should you need assistance during the conference call you may see non operator by pressing star and zero.
No I'd like to turn the conference over to Kristen Gulf Betty I forget if director of Investor Relations. Please go ahead Matt.
Thank you Carl good evening, everyone and thank you for joining US with me today on the call is Dr. show Blanchard, President and Chief Executive Officer, and Soviet Young Chief Financial Officer of Annika. During today's call Cheryl until they were you Anikas second quarter Twentytwenty financial results and cheap business highlights, which are summarized in our earnings release.
Today.
A copy of the earnings releases available on the Investor Relations section of the website at <unk> Therapeutics Dot com.
In addition, a slide presentation is posted on our website in the Investor Relations section under the events and presentations tab.
Thank you to take a moment now to open the file and follow the presentation along with us.
Please turn to slide two.
Before we begin please remember that certain statements made during this conference call constitute forward looking statements as defined in the Securities Exchange Act of linking Dirty for these statements are based on our current beliefs and expectations, including statements with respect to impacts of the cobot 19 pandemic fun Annika. These statements are subject to certain risks and.
Uncertainties, the company's actual results could differ materially from any anticipated future results performance or achievements. Please also see or as you see filing for more information about factors that could affect our results.
Certain financial members measures, we will discuss on this call our non-GAAP financial measures. We believe that providing these measures helps investors gain a more complete understanding about results and is consistent with how management views our financial performance.
Reconciliation of these non-GAAP financial results to the most comparable to GAAP measurement calculated and presented in accordance with the U.S. GAAP is available on the Investor Relations section of our website.
I will now turn the call over to our President and CEO Dr. show Blanchard Cheryl.
Thank you Christian and good evening.
We hope that everyone joining us on this call remains in good health, while we continue to navigate this ever shifting landscape.
Our thoughts and gratitude remain with all the committed healthcare workers around the world. We're on the front line and Selflessly, taking on this global pandemic.
[noise] as this is our first full quarter call to report since I became president and CEO I'm delighted to share that the annika team executed extremely well against both internal and external expectations.
As expected the suspension of elective procedures due to cobot had a material impact on our business.
Despite the cobot environment, we generated positive top and bottom line performance and surpassed aggressive organizational goals, including integration milestones all in the environment of a global pandemic.
That cross functional execution underscores the ability of our team to adapt overcome situational barriers and find new ways to deliver increased value to our customers shareholders and other key stakeholders with a continued focus on the patients who benefit from Anikas products.
Please turn to slide three.
Before diving into our second quarter results in business progress I'd like to discuss how we're continuing to navigate the evolving cobot 19 environment first and foremost our steps to safeguard the health and wellbeing of our employees and other stakeholders have paid off.
Remote and distance working new internal policies and other measures have been effective and maintaining a healthy organization and continuing to deliver our products to physician in their patient safely.
Manufacturing and supply chain operations have also continued with minimal disruption.
And our team and distribution partners have coordinated closely with medical facilities and surgery centers to ensure patients have had uninterrupted access to the treatments and implants they need.
We also maintained strong fiscal discipline during the quarter, focusing on cash preservation and strengthening our liquidity.
Our continued proactive and decisive action, including talent redeployment acceleration of integration activities and delivering products as procedural recovery ramps back up drove the business result in progress we achieved in the quarter and positioned us well for the future.
Please turn to slide four.
The leadership team that is successfully navigating this unique environment is now a combination of legacy Annika executive talented leaders the joined Annika through the recent acquisitions of carcass medical and Arthur surface and other recent additions to our team.
This enhanced team positions us very well for continued success in the current environment and as we work to grow annika in coming quarters in years.
There have been several key organizational changes and many team members, who deserve recognition for their contribution but today I would like to highlight a few key adds to our newly formed Annika executive team.
First burp racing, who was a co founder and executive at Park. It has been appointed senior Vice President of sales and marketing for the Americas region.
Partisan established orthopedic executive with a successful career and sales and marketing in sports medicine and prior to joining carcass. He served in commercial leadership roles at companies, including Arthrex Incent the nephew.
Steve Act, the former President and CEO at Arthur surface has been appointed Vice President of research and development.
Steve has a track record of designing and delivering breakthrough solutions in the joint preservation and restoration and sports Medicine markets. He also brings a wealth of orthopedic knowledge from his prior work experience that when the tech now Con Ed and Smith <unk> nephew.
Mark Brunsvold another co founder and the former President of Purkiss, We'll continue to lead the legacy Park is operations as president of Sports Medicine.
Mark brings a significant background is innovating and manufacturing in the sports medicine field from his prior work experience developing in manufacturing products for Arthur acts as the owner of machine metals.
Finally, James chain Senior Vice President of International sales and marketing has assumed responsibility for Anikas operations in pad, what Italy in order to fully leverage our growing international business.
James brings significant sales marketing and general management experience in the sports and regenerative medicine spaces from his extensive experience at Smith <unk> nephew.
The more time I spend with his team the more excited I become about you know because future and our ability to drive growth to new levels.
Now turning to slide five.
We delivered a strong revenue performance in the quarter with total revenue growing year over year. This exceeded our kobin planting expectations for the quarter, even in light of the procedural slowdowns due to the pandemic.
The temporary suspension of elective procedures resulted in an organic top line decline of $5.9 million during the quarter. However, inorganic revenue contributed an increase of $6.2 million in the quarter, which more than offset the drop in resulted in year over year topline growth of 1%.
This speaks to the success of our strategic initiatives and the strength of our newly expanded more diversified business.
I'm also very encouraged by the improvement we experienced over the last couple of months as result of restrictions easing on elective procedures across major markets, even with recent covance setbacks in certain regions.
Orthopedic joint preservation and restoration volumes were at about 25% of historical levels in April and rose to around 50% in may and over 80% in June on a pro forma basis.
July's orthopedic joint preservation and restoration run rate volumes are around 75% of 2019 levels also on a pro forma basis.
The procedural recovery was particularly evident in ambulatory surgery centers are ASV and office based activity, where physicians have had the ability to implement safety protocols that have allowed certain appointments and procedures to resume.
Our tracking rapid response in adaption to the shifting environment has allowed us to maintain relevance in the marketplace and even gain and training customers during the period.
[noise], it's important to remember that the vast majority of our products are used in either office based procedures for the away pain management injectable side of business.
Or surgeries performed in the AMC setting.
We anticipate hospitals will continue to pay special challenges with the influx of cobot patients and we expect continued depressed levels of elective procedures in the hospital and possibly assay in office, setting, especially as cold and hot spots emerge in different geographies.
Our current product mix that favors non hospital based procedures puts us in a strong position to continue our positive momentum going forward, depending on the covert status in a given geography.
An additional factor benefiting second quarter revenue was the stable order flow during the quarter for Monovisc and Orthovisc from our U.S. commercial partner due to order timing and contractual terms.
We expect domestic orders for Orthovisc and Monovisc to ease in the second half of the year to level off inventory due to lower end market sales in Q2 as a result is coated.
Please turn to slide six.
We made accelerated progress against our integration plan during the quarter. Most importantly, we fully integrated our U.S. commercial team, forming a single seamless organization to support our expanded product portfolio.
These changes include the senior management changes I mentioned earlier, the implementation of shared marketing and sales operations function and an optimized direct sales representative structure and scaling plants.
We entered the third quarter with 35 direct sales professionals in the U.S. In addition to a specialized group of sales support and marketing personnel.
Final elements of the integration that will continue into next year include consolidation and implementation of operating system and the prioritization of our robust product pipeline, which will be discussed on the next earnings call.
Turning to slide seven.
We also made changes in our R&D team in an effort to streamline and accelerate development of our many promising new product development programs.
We made progress evaluating our robust product pipeline and we are on track to roll out our new R&D roadmap to investors on our third quarter earnings call.
Q2 was a very active time for our product development and regulatory teams, we gained U.S. regulatory clearance for six new sports medicine surgical devices in instruments to enable procedures ranging from rotator cuff repair the arthroscopic me repairs and treating arthritis damage in the hand and wrist.
These products will be commercialized through Anikas recently integrated sales and marketing team through the third quarter of 2020.
We also expanded the taxes that franchise, our surgically deliver regenerative therapy to treat bone insufficiency fractures with the launch of a small bone canyon with that.
This line extension was developed with input from foot and ankle surgeons to enable improved and more accurate access and small joints and extremities and we'll address unmet patient needs in those joint.
In addition, we achieved our first sales of single in Australia in the quarter and continued international expansion of our joint pain management portfolio with single and Monovisc regulatory approvals in Finland, and single Monovisc and Orthovisc approvals in Serbia.
With respect to clinical trials, we've continued to work with clinical trial sites and zero partners to determine how and when we can safely start new or resume ongoing studies.
Well, we're not yet ready to provide updated timing for the single pilot study or the Hyalofast three phase three trial. We are optimistic that we will be able to provide you guidance by the time, We report our third quarter results in October.
We're ready to move ahead with these clinical trial plans as soon as it is safe to do so in the current coven environment.
And continued to be excited to pursue both of these products in the U.S. market based on our commercial experience with them internationally.
I will now turn the call over to Sylvia to review, our second quarter results and I will wrap up with some additional comments on the quarter before opening the lines for questions.
Sylvia.
Thank you Sheryl.
Please turn to slide number eight.
Total revenue for the second quarter of Twentytwenty increased 1% and 20% year over year for the three and six month periods respectively.
Revenue growth for the quarter was driven primarily by orthopedic joint preservation and restoration products due to the acquisitions of parkas medical and ortho surface.
This was partially offset by the lower joint pain management revenue under the cobot environment.
We expect U.S. purchase orders for Orthovisc and Monovisc to east in the second half of the year.
As a result of inventory levels by our commercial partner due to cobot.
As part of the integration of park, it's an article surface, we have decided to prioritize and over time discontinue certain legacy annika products in the future.
These are low volume and low margin, primarily wouldn't care relate at noncore products.
In the second quarter, we recorded 2.9 million noncash charges related to this product rationalization of which 1.9 million was included in the cost of revenue and 1 million was included in the selling general administrative expenses.
As expected, we also incurred noncash acquisition related amortization expense of 3.8 million in the quarter and cost of product revenue.
The result of these noncash charges impacted product gross margin by 19 percentage points year over year.
[noise] Cobot also negatively impacted our topline, resulting in lower royalty revenue and lower manufacturing volumes together impact at product gross margin by 14 percentage points for the quarter.
As a result product gross margin was 45% for the quarter compared to 78% for the second quarter of 2019, and 60% for the first quarter of Twentytwenty.
The Q2 product Roche gross margin is primarily a result of nonrecurring items and cobot and Barnett.
And therefore should not be indicative of our future performance.
Cost of product revenue, R&D, and SGN, a expenses in a quarter, where $36 million compared to 18.5 million in a second quarter of 29 team.
Cost of product revenue increased one point, sorry increased 10.1 million due to the drivers previously discussed.
Selling general and administrative expenses increased 7 million due mostly to increased selling and marketing expenses related to the company's expanded sales infrastructure and intangible asset charges approximately $1 million relate it to the rationalization of certain legacy products, which we just.
Just earlier.
Total operating expenses for the second quarter of Twentytwenty also include at 4.2 million of increase in fair value of contingent consideration liability.
These were associated with the recent acquisitions of park is and ourselves starfish.
This charge was recorded as an expense in the second quarter.
The increase in contingent liability is primarily a result of better than expected revenue performance in the second quarter due to easing cobot restrictions in certain regions and a related improvements and revenue.
Net loss for the quarter was 7.7 million or 54 cents loss per diluted share count.
Compared to net income of 9.4 million or 67 cents per diluted share in a second quarter of 2019.
Excluding the noncash charges discussed earlier, we achieved net income and positive EBITDA for the quarter.
Non-GAAP adjusted net income for the second quarter of Twentytwenty was 1.2 million or nine cents per diluted share.
Adjusted EBITDA was 5.6 million for the quarter compared to 14.8 million for the second quarter of last year.
The decrease in adjusted EBITDA was primarily due to increases in cost of product revenue and related revenue mix as well as selling and marketing expenses discussed earlier.
Adjusted EBITDA as defined by the company has U.S. GAAP net income.
Excluding depreciation and amortization interest and other income or expense income taxes share based compensation expense acquisition related expenses and other charges noncash charge related to goodwill impairment in the first quarter and change in fair value of contingent consideration. So.
Shade it with our recent acquisitions and as a result of the cobot 19 pandemic.
We ended the quarter with a solid $144 million in cash and investments on our balance sheet.
In April we drew down 50 million from our existing credit facility to strengthen liquidity in light of Cobot 19.
We have also implemented a number of short term internal expense controls and are prioritizing business initiatives to conserve cash flow.
And continue selected investment in critical strategic initiatives for future growth.
We're continuing to suspend our financial guidance for the remainder for for the full year of Twentytwenty until our visibility into revenue trends impacted by cobot improves.
Importantly, the long term fundamentals of our business remains strong and we're well positioned to navigate this period of uncertainty.
That concludes my comments and I would now turn the call back over to Cheryl.
Sure. Thank you Sylvia.
Thank you Sylvia.
I'd like to remind you that as previously announced Soviet Chung claims to step away from her role at Annika next month.
We have proceeded with a timely search to identify Soviet successor, and have evaluated some truly excellent candidates I feel strongly we will be able to name a top notch CFO in the not too distant future.
On behalf of the board and management team I want to thank Sylvia for her years of service in building. This company and also for the support she has provided to me and so many of our colleagues over the years. Thank you Sylvia truly we will always be grateful for your leadership.
And to wrap up the second quarter.
We experienced an unprecedented impact on procedure volumes in our business in general as a result with coated.
As jarring is that was we leaned into the challenge turning our efforts to actively tracking the situation through multiple channels with the goal of quickly returning to full commercial activity as soon as it safely possible.
We continue to aggressively monitor leading indicators of hospital surgery Center in office based activity and engage with our customers and distributors. We also moved quickly on integrating our commercial organizations to leverage our full product portfolio across the full sales team.
That vigilant analysis and rapid response allowed us to be equipped when our customers were ready.
Our performance in the second quarter underscores the resolve of our leadership team and the strength depth and new diversity of our product portfolio propelling us organization forward.
While we are not provided guidance at this time due to the uncertainty presented in the current cobot environment, our business fundamentals and product pipeline remains strong and demand for our innovative products is robust.
We're now ready to take your questions. Thank you.
Thank you.
We will now begin the question answer session to join the question Q Human Press Star then one on your telephone keypad.
You will hear a tolling acknowledging your request.
If you're using a speakerphone please pick up your handset before pressing any key.
I would draw your question. Please press Star then too.
Well pause for a moment as color join the queue.
The first question come from Jim Sidoti with Sidoti and company LLC. Please go ahead.
[noise]. Good afternoon can you hear me.
We can't really good afternoon James.
Okay, Great first Sylvia I, just want to say good luck with whatever adventures or next to you and you'll be missed.
Thank you appreciate it Jim.
HM no with regards to the quarter you indicated that you U.S. partner, which can quit contractually obligated are used to to make some purchases can you just give us an order of magnitude or what that revenue was from them and.
How much do you feel well that go down do you expect in the second here for the year [noise].
Yes, so the revenue from our Orthovisc and Monovisc products in the U.S. was roughly about 55% of our Q2 revenue.
And from a mix standpoint, you used to be more or less roughly between product and and royalty. The due to the cobot pandemic situation. The royalty component is much smaller than than before and as Charles mentioned earlier. This this factor.
Had impacted our first half of the of the year revenue as our U.S. partner continued with their purchase of for the second quarter. They did not reduce their inventory purchase.
And this is due to timing of order placement as well as contractual terms. However, we did see that royalty revenue from domestic orthovisc and monovisc sales during the quarter a decline and it was negatively impacted by coal but.
We do expect the second half the year for Orthovisc and Monovisc in the U.S. product purchase to be lighter in the second half at the year comparing to the first half of the year as a result of inventory leveling by our commercial partner bad. The same time, we think that the royalty revenue will continue to pick up as our.
Office space procedure resumes in the U.S. So at this point, we're not really in a position to provide a quantitative numbers in terms of those expectations and I think you may remember dose, we do get compensation for my partner in two different ways first is that product transfer price.
When we sell them.
Products and second is as of royalty when they sell the product tie into the markets and the dynamic of the to come about components that I discussed discuss just now and what Sheryl was talking about will impact the first half and the second half from a revenue back standpoint, So first half we had more.
Our product revenue less royalty revenue the second half at the year, we'll be seeing the reserve and resource but in terms of dollar size, we're not in a position to provide that information.
Okay, but you do expect it'll be lower over the combined revenue will probably be lower in the second tariffs in the first two if you go right.
[noise] theres the potential at this time, it's difficult to say because the royalty component is very much driven by the end market sales and with the uncertainties surrounding coal batch, it's very difficult to project what that revenue trends will continue to look like.
Okay. So I think what I'm hearing is gave procedures picked up.
Significantly.
The increase in royalty wearable revenue might be enough to offset the decline in product sales.
Yeah, that's very much dependent upon the Colbert recovery and they end market sales that's correct.
Okay and then.
The acquisition related expenses that entirely non cash utilization that 3.8 mood or were there were other expenses and live.
So there are two components to it roughly about half of it is related to amortization of intangible assets and the remaining is related to amortization of inventory markup, which we do expect to deplete between.
We now and sometime in 2021 at the rate of that obviously is tied to.
The the sales and the cobot recovery of targets and our whole surface products.
Okay. So so the faster than things recover them quicker that that step up in inventory charge goes away but.
It sounds like a.
There will always be around 2 million of.
Well for quarter of non cash amortization going forward.
[noise] [noise] for for the knee, yes for the near term related to the intangible asset amortization that is correct and within that bucket. There are three different categories of intangible assets and the use and the estimated economic lives a ranges.
Five years to 15 years, so depending on the their remaining useful life, obviously, it will impact the sizing the of the amortization expense.
But those are much longer term comparing to the inventory markup amortization, which are expected to see where its fleet at bye bye.
By sometime in 2021.
But depending on how sales go there could come sooner or later.
That's exactly right.
Alright, and then can you just repeat the monthly break out I think you said it was oh on procedures, 25%, 50%, 80% is that what we consider.
Yeah. This is Sheryl I said in April we were at about 25% of historical this was for the joint preservation and restoration part of the business, 25% of historical levels on a pro forma basis May was at 50 June was over 80, and then July is tracking.
At around 75%.
Okay.
Are you seeing any positions report you know increasing activity.
From patients, who maybe a little bit hasn't been go into the hospital Ceos the total nuclear suites.
Yeah, that's a it's a a conversation we've had with a lot of a with a lot of customers and and marketing partners I think that there's an element of that taking place, but it's difficult to track with data. So while I would tell you that we believe that's and intuitive a reasonable intuitive somehow.
And to make we don't have a lot of data to back it up but we certainly here of of cases, where that is happening and I think that you know as as Colvin progress is we could be seeing that as a trend.
And then let US one for me in the quarter.
As today it was around 14 into half mill and it I think you said there was about a million dollars of.
A one time.
The what are the.
Uh huh.
So should we think.
No.
At around 30 in the half million a quarter no at this sales level and obviously it is sales go up it would go up a little but is 13 into half million or could be slowly.
Thanks.
So Jim.
In the baseline number it's difficult to to give a comment John because we're currently under coal bed. So assuming that you know all the conditions are similar to this past Q2, I would say that it's a it's a good baseline number the 1 million a nonrecurring item was.
Related to the product rationalization activity, which we spoke about you are correct in saying that the SGN a line will scale with five topline revenue increase because part of that is related to a commission and other sales related expenses associated with.
Topline revenue at this point, we are not providing any a baseline or projection.
Information for our operating expenses I think we'll be in a much better positioned to do so as we have.
As we exit from cobot and have a more normalized business to be gosh.
Okay. All right, though is that for me. Thank you and a good good work Sylvia.
Thank you very much Jim.
Thanks, Jim.
Thank you.
Once again, if you have a question. Please press Star then one.
The next question comes from Mike Petusky from Barrington Research. Please go ahead.
Hi, Thank you. So I just wanted to clarify the 25%, 50%, 80%, 75% that that that's procedure volume in the space or that's your sort of your revenue trends in joint preservation and restoration.
Yeah that is our outweigh forgot your volume trends.
Okay.
Yeah, if the it's our procedure volume trends.
Gotcha, Okay, great and then on the product rationalization. So <unk> is it a million dollars.
For the quarter was awarded a million dollars annualized. Furthermore to calm can you just talked about.
You know sort of the totality of what you guys are doing and.
Rationalizations and I'm going to revenues.
You know in play here. Thanks.
Sure. So in total the product rationalization related charge was EUR 2.9 million 1.9 went through cost of product revenue and 1 million went through SGN. A so this is related to.
It de prioritizing or de focusing on noncore low margin and low volume products and mostly in the one care business area. So they're not a material to our revenue and certainly a in the noncore.
Noncore aspects of our of our business I'm. So it is a onetime event.
Okay all right.
<unk> million or $2 million, a year or something less than that.
Yeah, it's much less than that.
Okay, Okay great.
What about a it probably is sometimes you guys have given sort of pricing trends in monovisc and orthovisc was or was there any price cutting.
In Q2, and you know is there anything you can share.
Sure.
You know your best guess is too.
Second half.
Yep, so from a pricing in the U.S. standpoint for Orthovisc and Monovisc, what we saw was on a sequential quarter basis.
There was the pricing for Orthovisc was a pretty stabilized.
<unk> for Monovisc, we saw a modest decline in the second quarter in a low single digit range and it's it's difficult to a project what second half the year would look like.
As you know, we don't have a control and don't have full visibility into that aspect of the business. The information that I shared in terms of fee Q2 activities I think our within expectation from our standpoint.
Okay, Great and then Sheryl I.
They have heard this more optimistic leaving you commented.
Commentary around visibility for single and other trials.
It seems you seem to be saying that you thought you would have some visibility in terms of restarting knows when you guys. Do your Q3 conference call did I hear that is that what you were saying or did I. Miss this here, what you're trying to get across there no. You heard me correctly, you know we feel like.
We're optimistic that for the Q3 call that we will be able to provide an update on progress and timing for those trials.
It's it's still obviously very dependent on the cobot environment and in specific to clinical trial site geography is relative to what's going on with Cove. It in a given geography, but we've continued to make progress with.
Bidding up new sites with the Hyalofast trial is we had talked about doing on prior calls and implementing all of the start up work for the single pilot trial.
The work has continued there and we're obviously seeing very close to the sites through our own communications and through our CRL partner Communications and we feel like by Q3 will we'll be able to provide some updates. Okay. Just wanted to be absolutely crystal clear on this that you're making progress in terms of like sites surface.
Asian in that sort of thing, but they're on actual active trials going on in the company at this point are there.
So the Hyalofast trial isn't active trials that have suspended enrollment because of coated right. So that trial remains active duty thing golf pilot trial has sort of completed all the startup activities to the point that we can take them up until we start enrolling patients, which we have not done.
On yet because we won't do that until we feel we feel like we can do it safely and execute on the trial. According to the protocol. So yeah. That's correct me, neither suspended or not yet started enrollment and that's the update we feel like we'll be able to.
We're optimistic we can provide on the next call.
Gotcha, Okay last question, Hi, obviously [laughter].
He sort of retirees States, Florida, Arizona, or a southern California places like that have been hit hard with co bid a the last or let's say four to six weeks I would assume that those are also places where are you guys have pockets of strength.
And your business, particularly in it you know like Monovisc, and Orthovisc and and so on do you have any sense of how much exposure you have in some of these sort of southern orphan Sunbelt Southwest's type states that are heavy with a retirees.
[noise], Yeah, we've obviously cap as close to track of those dynamics as we can and what I can tell you is that in those states and frankly in other places you know we have business around the world and around the United States that as these hot spots are popping.
We see a elective procedures shutdown in a city or a state for a week for a month and so there's there's definitely some impact in and.
I would say very active start stop activities in some of those regions what that impact looks like it's very difficult to predict and that's why we felt like the best we could do with at least give you how we're tracking in the month of July because that's pretty close to actual data at this point in time and then we're going to.
Obviously continue to tracking closely going forward.
Could I just ask one clarifying question in July do you actually have you seen any sort of dip in second half of July versus first half in July we came off the call yesterday were essentially they communicated.
I had seen a material dip in second half versus first half.
I would say that we have not seen that.
Alright, very good thank you.
Thank you very much my Kevin I say.
Thank you.
This concludes the question answer session I would now like to turn the conference back over to Sherilyn Blanchard for any closing remarks.
Thank you Carl and thank you for your time today, everyone. We look forward to updating you as we continue to deliver progress on our strategic initiatives have a great evening and please everyone stay well.
Thank you.
This concludes today's conference call you may disconnect. Your lines. Thank you for participating and have a pleasant day.
[music].
[noise] [noise].
[noise].